(Q41138516)

27 September 2017

title

JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms (English)

1 reference

27 September 2017

author name string

Sowmya Parampalli Yajnanarayana

1

1 reference

27 September 2017

Thomas Stübig

2

1 reference

27 September 2017

Isabelle Cornez

3

1 reference

27 September 2017

Haefaa Alchalby

4

1 reference

27 September 2017

Kathrin Schönberg

5

1 reference

27 September 2017

Janna Rudolph

6

1 reference

27 September 2017

Ioanna Triviai

7

1 reference

27 September 2017

Christine Wolschke

8

1 reference

27 September 2017

Annkristin Heine

9

1 reference

27 September 2017

Peter Brossart

10

1 reference

27 September 2017

Nicolaus Kröger

11

1 reference

27 September 2017

Dominik Wolf

12

1 reference

27 September 2017

language of work or name

English

0 references

publication date

30 March 2015

1 reference

British Journal of Haematology

27 September 2017

published in

1 reference

27 September 2017

volume

169

1 reference

27 September 2017

issue

6

1 reference

27 September 2017

page(s)

824-833

1 reference

IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells.

27 September 2017

cites work

1 reference

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

21 January 2018

1 reference

EGF signalling and rapamycin-mediated mTOR inhibition in glioblastoma multiforme evaluated by phospho-specific flow cytometry

21 January 2018

1 reference

General nature of the STAT3-activated anti-inflammatory response.

21 January 2018

1 reference

Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation.

21 January 2018

1 reference

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

21 January 2018

1 reference

The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo

21 January 2018

1 reference

Remission of recalcitrant dermatomyositis treated with ruxolitinib.

21 January 2018

1 reference

Partial impairment of cytokine responses in Tyk2-deficient mice

21 January 2018

1 reference

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat

21 January 2018

1 reference

Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib.

21 January 2018

1 reference

A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R

21 January 2018

1 reference

Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts.

21 January 2018

1 reference

Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedback

21 January 2018

1 reference

The V617F JAK2 mutation and the myeloproliferative disorders

21 January 2018

1 reference

JAK-STAT signaling: from interferons to cytokines

21 January 2018

1 reference

Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components

21 January 2018

1 reference

Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis

21 January 2018

1 reference

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.

21 January 2018

1 reference

Expression of constitutively active STAT3 can replicate the cytokine-suppressive activity of interleukin-10 in human primary macrophages.

21 January 2018

1 reference

Identification of an acquired JAK2 mutation in polycythemia vera

21 January 2018

1 reference

Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348).

21 January 2018

1 reference

CD4 T cells: fates, functions, and faults

21 January 2018

1 reference

Differentiation of effector CD4 T cell populations (*)

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.13373

1 reference

27 September 2017

1 reference